- The Company has shipped pre-commercial quantities of CBD full spectrum oil containing THC, to support the development of a full spectrum product for the Brazilian market.
TORONTO and RIONEGRO, Colombia, June 6, 2022 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today announced an initial shipment of a CBD full spectrum extract with THC content to a well-established Brazilian Pharmaceutical company (the “Customer”) to support additional product development efforts, with the potential to become a key supplier as these products come to market. The Customer is expected to develop, and bring to market, a CBD full spectrum product using PharmaCielo’s API 1.
This is the second product being developed by this Customer using PharmaCielo APIs. The first, which uses PharmaCielo’s CBD isolate as an API, is currently under review by Anvisa and is expected to be approved in the next several months, with the product launching in Brazil soon after approval.
Management Commentary
Bill Petron, CEO of PharmaCielo, commented, “We are pleased to support our partner in Brazil as they seek to develop a CBD full spectrum product. With a population of over 200 million and very few…